Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Development of a fluorescence polarization assay for the molecular chaperone Hsp90.

Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N, Chiosis G.

J Biomol Screen. 2004 Aug;9(5):375-81.

PMID:
15296636
2.
3.

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Chiosis G, Caldas Lopes E, Solit D.

Curr Opin Investig Drugs. 2006 Jun;7(6):534-41. Review.

PMID:
16784024
4.

Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.

Moser C, Lang SA, Stoeltzing O.

Anticancer Res. 2009 Jun;29(6):2031-42. Review.

5.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
6.

Geldanamycin and its anti-cancer activities.

Fukuyo Y, Hunt CR, Horikoshi N.

Cancer Lett. 2010 Apr 1;290(1):24-35. doi: 10.1016/j.canlet.2009.07.010. Epub 2009 Oct 21. Review.

PMID:
19850405
7.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

8.

Discovery and development of heat shock protein 90 inhibitors.

Taldone T, Sun W, Chiosis G.

Bioorg Med Chem. 2009 Mar 15;17(6):2225-35. doi: 10.1016/j.bmc.2008.10.087. Epub 2008 Nov 6. Review.

Supplemental Content

Support Center